Evaluation of the Pathogenesis of Decreasing CD4+T Cell Counts in Human Immunodeficiency Virus Type 1–Infected Patients Receiving Successfully Suppressive Antiretroviral Therapy
Citations Over TimeTop 15% of 2009 papers
Abstract
Most human immunodeficiency virus (HIV)-infected individuals experience increases in peripheral CD4(+) T cell counts with suppressive antiretroviral therapy (ART) that achieves plasma HIV RNA levels that are less than the limit of detection. However, some individuals experience decreasing CD4(+) T cell counts despite suppression of plasma viremia. We evaluated 4 patients with a history of CD4(+) T cell decline despite successfully suppressive ART, from a median of 719 cells/mm(3) (range, 360-1141 cells/mm(3)) to 227 cells/mm(3) (range, 174-311 cells/mm(3)) over a period of 18-24 months; 3 of the patients were receiving tenofovir and didanosine, which may have contributed to this decrease. There was no evidence of HIV replication, nor of antiretroviral drug resistance in the blood or lymphoid tissue, or increased proliferation or decreased thymic production of naive CD4(+) T cells. All 4 patients had significant fibrosis of the T cell zone of lymphoid tissue, which appeared to be an important factor in the failure to reconstitute T cells.
Related Papers
- → A Randomized Study of the Safety and Antiretroviral Activity of Hydroxyurea Combined with Didanosine in Persons Infected with Human Immunodeficiency Virus Type 1(2000)22 cited
- → Early and Prolonged Decrease of Viremia in HIV-1-Infected Patients Treated with Didanosine(1995)13 cited
- → Faculty Opinions recommendation of Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.(2009)
- → Maintenance of antiretroviral therapy despite low-level viremia in HIV patients appears to be appropriate(2004)
- → Faculty Opinions recommendation of Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy.(2008)